- Previous Close
22.78 - Open
22.66 - Bid 23.09 x --
- Ask 23.10 x --
- Day's Range
22.66 - 23.22 - 52 Week Range
18.17 - 28.58 - Volume
7,680,005 - Avg. Volume
7,354,868 - Market Cap (intraday)
14.524B - Beta (5Y Monthly) --
- PE Ratio (TTM)
18.47 - EPS (TTM)
1.25 - Earnings Date --
- Forward Dividend & Yield 1.20 (5.20%)
- Ex-Dividend Date Oct 10, 2024
- 1y Target Est
--
Jiang Zhong Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of Chinese patent medicines and health foods in Mainland China. The company offers OTC products for spleen and stomach, intestinal tract, anorectal, throat cough and asthma, supplements and minerals, and chronic diseases. It also offers health products for high-end nourishment, rehabilitation nutrition, gastrointestinal health, liver and gallbladder health, dietary nutrition, basic vitamins, personal care essential oils, and other businesses; and prescription products. The company sells its products under the Jiangzhong, Lihuo, Chuyuan, Shenlingcao, Yang Jisheng, and Songhai brands. Jiang Zhong Pharmaceutical Co.,Ltd was founded in 1969 and is headquartered in Nanchang, China. Jiang Zhong Pharmaceutical Co.,Ltd is a subsidiary of China Resources Jiangzhong Pharmaceutical Group Co., Ltd.
www.jzjt.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600750.SS
View MorePerformance Overview: 600750.SS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600750.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600750.SS
View MoreValuation Measures
Market Cap
14.52B
Enterprise Value
13.51B
Trailing P/E
18.47
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.28
Price/Book (mrq)
3.76
Enterprise Value/Revenue
3.05
Enterprise Value/EBITDA
11.60
Financial Highlights
Profitability and Income Statement
Profit Margin
17.77%
Return on Assets (ttm)
9.54%
Return on Equity (ttm)
19.24%
Revenue (ttm)
4.44B
Net Income Avi to Common (ttm)
788.19M
Diluted EPS (ttm)
1.25
Balance Sheet and Cash Flow
Total Cash (mrq)
1.02B
Total Debt/Equity (mrq)
0.01%
Levered Free Cash Flow (ttm)
179.6M